{"denoms":[{"counts":[{"groupId":"BG000","value":"314"},{"groupId":"BG001","value":"314"},{"groupId":"BG002","value":"628"}],"units":"Participants"}],"groups":[{"description":"Participants received pembrolizumab 200 mg IV on Day 1 of every 21-day (3-week) cycle for up to 35 administrations (up to approximately 25 months).","id":"BG000","title":"Pembrolizumab"},{"description":"Participants received Investigator's choice of paclitaxel 80-100 mg/m\\^2 IV on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR docetaxel 75 mg/m\\^2 IV on Day 1 of every 21-day (3-week) cycle, OR irinotecan 180 mg/m\\^2 IV on Day 1 of every 14-day (2-week) cycle (up to approximately 19 months).","id":"BG001","title":"Chemotherapy"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.4","value":"62.6"},{"groupId":"BG001","spread":"9.6","value":"62.0"},{"groupId":"BG002","spread":"9.5","value":"62.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"84"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"273"},{"groupId":"BG001","value":"271"},{"groupId":"BG002","value":"544"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"44"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"288"},{"groupId":"BG001","value":"273"},{"groupId":"BG002","value":"561"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"23"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"126"},{"groupId":"BG001","value":"122"},{"groupId":"BG002","value":"248"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"179"},{"groupId":"BG001","value":"172"},{"groupId":"BG002","value":"351"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"15"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"109"},{"groupId":"BG001","value":"117"},{"groupId":"BG002","value":"226"}],"title":"PD-L1 CPS ≥10"},{"measurements":[{"groupId":"BG000","value":"199"},{"groupId":"BG001","value":"194"},{"groupId":"BG002","value":"393"}],"title":"PD-L1 CPS <10"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"9"}],"title":"Not Evaluable"}]}],"description":"Participants were assessed for their PD-L1 tumor expression levels by immunohistochemistry assay on tumor tissue from a newly obtained biopsy. PD-L1 CPS was calculated as the number of PD-L1 positive cells (tumor cells, macrophages, lymphocytes) divided by the total tumor cells and is expressed as a percentage. Participants were classified based on their PD-L1 tumor status as being either PD-L1 CPS ≥10 or PD-L1 CPS \\<10.","paramType":"COUNT_OF_PARTICIPANTS","title":"Programmed Death-Ligand 1 (PD-L1) Status: Combined Positive Score (CPS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"121"},{"groupId":"BG001","value":"122"},{"groupId":"BG002","value":"243"}],"title":"Asia"},{"measurements":[{"groupId":"BG000","value":"193"},{"groupId":"BG001","value":"192"},{"groupId":"BG002","value":"385"}],"title":"RoW"}]}],"description":"Participants were classified based on their geographic region of enrollment as either being from Asia or from outside of Asia (Rest of World \\[RoW\\]).","paramType":"COUNT_OF_PARTICIPANTS","title":"Geographic Region","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"199"},{"groupId":"BG001","value":"204"},{"groupId":"BG002","value":"403"}],"title":"Squamous cell carcinoma"},{"measurements":[{"groupId":"BG000","value":"115"},{"groupId":"BG001","value":"110"},{"groupId":"BG002","value":"225"}],"title":"Adenocarcinoma of esophagus & EGJ Siewert type I"}]}],"description":"Participants were classified based on their tumor histology (cell type) as either having squamous cell carcinoma or having adenocarcinoma of esophagus and esophagogastric junction (EGJ) Siewert type I.","paramType":"COUNT_OF_PARTICIPANTS","title":"Tumor Histology","unitOfMeasure":"Participants"}]}